Vanderbilt Vaccine Research Program Archives
Nov. 4, 2022—A Vanderbilt study finds that Moderna’s COVID-19 vaccine is safe and effective in children 6 months to 5 years of age.
Sep. 7, 2022—Vanderbilt is seeking about 30 healthy adults of diverse backgrounds to participate in a national clinical trial to evaluate alternative strategies for administering the monkeypox vaccine
May. 12, 2022— by Bill Snyder Moderna’s COVID-19 vaccine is safe and generates robust immune responses in children ages 6 to 11 years, a national clinical trial co-led by Vanderbilt University Medical Center vaccine expert C. Buddy Creech, MD, MPH, has found. The two-dose vaccine (given approximately one month apart) led to antibody responses in more than...
Feb. 24, 2022—A Vanderbiltl study found that children who received the COVID-19 vaccine who had not previously been diagnosed with COVID infection are unlikely to be diagnosed with multisystem inflammatory syndrome in children (MIS-C).
Feb. 3, 2022—A Vanderbilt study found that five days of antibiotics is superior to 10 days for children with community-acquired pneumonia who are not hospitalized.
Dec. 8, 2021—Vanderbilt University Medical Center infectious disease experts advise this is the season to think very wisely about planned get-togethers.
May. 12, 2021—Heparin and platelets are discouraged as treatment for patients who develop blood clots in the brain and low platelet counts 6-15 days after receiving Johnson & Johnson’s Janssen COVID-19 vaccine, following a clinical investigation review of 12 U.S. cases conducted by the CDC and institutions including Vanderbilt University Medical Center.
Apr. 2, 2021—Vanderbilt University Medical Center is participating in a national phase 1 clinical trial in healthy adults of an investigational vaccine against the B.1.351 variant of the COVID-19 virus that was first identified in South Africa.
Dec. 16, 2020—The development of the vaccines, monoclonal antibodies and antiviral drugs that ultimately will defeat COVID-19 wouldn’t have been possible had it not been for the unflagging and selfless efforts of a global army of research nurses, laboratory personnel, recruiters and other staff.
Nov. 2, 2020—Vanderbilt University Medical Center has begun recruiting up to 250 participants for a Phase 3 clinical trial testing an investigational COVID-19 vaccine candidate developed by the Janssen Pharmaceutical Companies of Johnson & Johnson.
Jun. 4, 2020—The investigational antiviral drug remdesivir can shorten the time to recovery in adults hospitalized with COVID-19, according to preliminary results of a clinical trial published last month in The New England Journal of Medicine.